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ABSTRACT 
Background: Patients with hepatocellular carcinoma (HCC) beyond the traditional criteria (advanced 
HCC) are typically offered palliation, which is associated with a 3-year survival rate lower than 30%. 
This study aimed to describe the outcomes for a subset of patients with advanced HCC who satisfied 
the Extended Toronto Criteria (ETC) and were listed for liver transplantation (LT). 
Materials & Methods: All patients listed in the Toronto liver transplant program with HCC beyond 
both the Milan and University of California, San Francisco criteria were included in this study. Data 
were extracted from the prospectively collected electronic database. All radiological images were 
reviewed by two independent radiologists. The primary endpoint was patient survival. 
Results: Between January 1999 and August 2014, 96 patients with advanced HCC were listed for LT, 
and 62 (65%) of these patients received bridging therapy while on the waiting list. Bridging therapy 
led to a significant reduction in tumor progression (p=0.02) and tumor burden (p <0.001). The 
majority of those listed underwent LT (n=69, 72%). Both tumor progression on waiting list (HR 4.973 
[1.599 – 15.464], p=0.006) and peak AFP ≥400ng/ml (HR 4.604 [1.660 – 12.768], p=0.003) were 
independently associated with waiting list dropout. Post-LT HCC recurrence occurred in 35% (n=24). 
Among those with HCC recurrence, survival was significantly better for those who received curative 
treatment (p=0.004). The overall actuarial survival rates from the listing were 76% at 1 year, 56% at 3 
years, and 47% at 5 years, and the corresponding rates from LT were 93%, 71%, and 66%. 




In most Western centers, palliation remains the only option for patients with advanced HCC with a 3-
year survival <30%. This study reports an improved survival with liver transplantation (71%, 66% at 3, 
5 years) of selected patients with advanced HCC. 
 
POSTSCRIPT 
This study was presented as an oral presentation in the International Liver Transplantation Society 
(ILTS) 22nd annual international congress (2016) held in Seoul, South Korea. 
 
INTRODUCTION 
Besides being a potentially curative treatment for early hepatocellular carcinoma (HCC) [1, 2], liver 
transplantation (LT) has the added advantage of removing the underlying cirrhosis and thereby 
minimizing the future risk of de novo HCC. Since the introduction of Milan criteria in 1996 [3], a post-
LT recurrence of <15% and a 5-year survival of >70% have become the acceptable norm [3, 4]. A 
number of expanded criteria have since been proposed, and shown to achieve comparable outcomes. 
The most widely recognized are the University of California, San Francisco (UCSF) criteria [5, 6], 
which are associated with a recurrence of ~10% and a 5-year survival of 75 – 80%. Generally, LT is not 
recommended for patients with advanced HCC [1, 2, 7] due to previous undesirable experience (high 
recurrence and poor survival) with unrestricted access [8].   
 
In most Western centers, palliative therapy remains the only treatment option for patients with 
advanced HCC. Locoregional modalities such as transarterial chemoembolization (TACE), 
stereotactic body radiation (SBRT) and systemic therapy (Sorafenib) are used for palliation, resulting 
in a 3-year survival of <30% at best [9, 10]. 
 
Improvements in understanding HCC biology and its role in predicting outcomes has rekindled the 
interest in LT for advanced HCC [11]. Encouragement from the improved outcomes with LT for HCC 
and dissatisfaction with the poor outcomes of palliative therapy has led to reexamination of the role 
of LT in advanced HCC. 
 
The Extended Toronto Criteria (ETC) place no restriction on the number HCC lesions or tumor size. 
Patients with any number and any size of HCC lesions are eligible for LT no evidence exists for 
vascular invasion or extrahepatic disease, no cancer-related constitutional symptoms are observed, 
and a targeted biopsy of the largest lesion does not show poor differentiation. Findings show that the 
LT outcomes for those beyond Milan but within the ETC were inferior compared to those within 
Milan, but were still acceptable [12]. However, no studies have specifically focused on the outcomes 
of patients with advanced HCC from the time of listing as reported herein. This study aimed to 
investigate and report on the outcomes of patients listed for LT with advanced HCC (within ETC) who 




MATERIALS AND METHODS 
Study population 
The analysis included patients listed in the Toronto liver transplant program for advanced HCC, 
patients listed for non-advanced HCC who had progressed to advanced HCC while on the waiting list, 
and patients listed for non-HCC indications who had developed advanced HCC while on the waiting 
list. Advanced HCC was defined using pre-transplant imaging demonstrating tumors beyond both 
Milan and UCSF criteria, but within the ETC. 
 
Demographic and clinical data were retrospectively extracted from the prospectively collected 
electronic transplant database. The study was approved by the Research Ethics Board (15–9989–CE). 
 
Assessment of change in tumor burden 
All patients underwent radiological imaging every 3 months, irrespective of bridging therapy and 
were independently reviewed by radiologists (S.G.B. and B.S.) blinded to the outcome. Tumor burden 
was assessed according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) [13]. 
At baseline, HCC lesions were divided into target and non-target lesions based on their longest 
diameter. Up to five lesions (instead of two lesions as specified by mRECIST), each measuring >1cm 
in at least one dimension were identified as target lesions. In the event of >5 lesions each measuring 
>1cm, the largest five lesions were identified as target lesions. All other lesions were identified as 
non-target lesions. 
 
Change in both target and non-target lesions were considered in assessing the overall change in 
tumor burden. In the event of bridging therapy, only the maximum length of the viable tumor was 
measured. The overall change in tumor burden was reported according to mRECIST criteria as 
complete response, partial response, stable disease, or progressive disease (summarized in 
Supplementary Table 1). 
 
Bridging therapy 
All listed patients were assessed for bridging therapy at the weekly multidisciplinary hepatoma board 
meetings. Patients without decompensation who were expected to have >6 months wait time 
underwent bridging therapy based on consensus opinion. In general, percutaneous ablation was 
recommended for lesions measuring 3cm; TACE was recommended for non-ablatable lesions with 
satisfactory liver function, and SBRT was considered for lesions not amenable to ablation and TACE. 
Surgical resection was not used as a bridging therapy, but patients with prior resection were included. 
 
The utility and technology of bridging therapy modalities have evolved during the study period.  In 
brief, these include (1) relative obsolescence of percutaneous ethanol injection for tumor ablation, (2) 
use of drug-eluting bead TACE over conventional TACE, (3) routine practice of superselective TACE, 
where possible, to maximize the impact on tumor and minimize the liver injury, and (4) the routine 
use of SBRT as a bridge to LT (since 2006) in patients not eligible for ablation and TACE [14]. 
 
Waiting list dropout 
Patients who experienced death or tumor progression beyond the ETC while awaiting transplant 
were considered dropouts. Those who remained within ETC despite tumor progression were not 
delisted.  
 Endpoints 
The primary endpoint was patient survival. This was defined from the time of listing and 
transplantation (for those who underwent LT) to dropout or death. Survivors were censored at the 
time of their last clinic visit. 
 
Data analysis and statistics 
Data are shown as median (interquartile range) or number (percentage) unless otherwise stated. 
Statistical analyses were performed using either GraphPad prism 5 (San Diego, CA) or SPSS for 
Windows v20. A p-value of <0.05 was considered significant. For analysis purposes, peak AFP was 
reclassified as a binary variable of <400ng/ml or ≥400ng/ml, as previously reported [15]; overall 
change in tumor burden was reclassified as progressive disease or non-progressive disease (includes 
complete response, partial response, and stable disease). Univariate analysis with Mann–Whitney U 
test or 1-way ANOVA (Kruskal-Wallis test) was undertaken to identify risk factors associated with 
waiting list outcome (transplantation versus dropout). A multivariable logistic regression model 
incorporating variables with a p-value of <0.10 on univariate testing was used to determine 
independent associations with waiting list dropout. Survival and disease recurrence estimates were 
calculated using univariate Cox proportional hazard models. Variables with a p-value of <0.10 on 
univariate testing were included in a multivariable Cox proportional hazard model. In all multivariable 
analyses, variables were incorporated using a backward selection process, with variables retained in 
the model if they maintained statistical significance. 
 
RESULTS 
1. Waiting list characteristics 
1.1 Demographics 
Between January 1999 and August 2014, 96 listed patients fulfilled the inclusion criteria (Table 1). The 
median age at listing was 59 years (IQR 52 – 63) and the majority (n=83, 86%) were men. Chronic 
Hepatitis C (n=41, 43%) was the most common etiology of liver disease, followed by chronic Hepatitis 
B, alcohol-related liver disease and non-alcohol-related steatohepatitis. 
 
1.2 Tumor burden 
At baseline, the median total number of HCC lesions (target and non-target lesions) was 5 (IQR 3 – 8), 
the median diameter of the largest lesion was 4.4cm (IQR 2.6 – 6.3), and the median total diameter 
of target lesions was 8.9cm (IQR 6.4 – 12.7). Immediately before to LT/dropout, the median total 
number of HCC lesions was 6 (IQR 2 – 11), the median diameter of the largest lesion was 3.0cm (IQR 
1.2 – 5.8), and the median total diameter of target lesions was 6.3 cm (IQR 1.2 – 11.4). More than half 
(n=55, 57%) had progressive disease with or without bridging therapy. 
 
1.3 Bridging therapy 
Nearly two thirds of the patients (n=62, 65%) received bridging therapy. The majority (n=49, 79%) 
received bridging therapy by a single method. The median number of bridging therapy sessions was 
2 (IQR 1 – 2) of any modality. 
 
The most common method was TACE (n = 47, 76%), used either alone (n = 38, 61%) or in combination 
with other methods (n = 9, 15%). Radiofrequency ablation was used for 18 patients (29%), whereas 
percutaneous ethanol injection therapy and SBRT, either alone or in combination, were used for four 
patients (6%). 
 
A comparison between patients who received bridging therapy and those who did not is summarized 
in Table 2. The distribution of etiology of liver disease was significantly different (p=0.02) between 
the two groups – hepatitis B was common in those who received bridging therapy, whereas hepatitis 
C and alcohol-related liver disease were more common among those who did not. The severity of 
liver disease (based on Sodium-MELD score) was less (p <0.001) in patients who received bridging 
therapy. Both peak AFP and tumor burden (total number of HCC lesions, diameter of largest target 
lesion and total diameter of all target lesions) at listing were similar between the two groups. As 
expected, bridging therapy led to a significant reduction in tumor burden. Receiving bridging therapy 
per se did not impact the waiting list outcome. However, tumor progression on waiting list was 
evident in a significantly greater proportion of patients who did not receive bridging therapy (n=25, 
74% vs. n=30, 48%; p=0.02).  
 
2. Waiting list outcome – transplantation versus dropout 
Nearly three fourths (n=69, 72%) underwent LT; majority received a deceased donor graft (n=57, 
83%). All but one dropped out due to tumor progression beyond the ETC – extrahepatic spread 
(n=10), macrovascular invasion (n=9), tumor progression with development of cancer-related 
symptoms (n=4), and tumor rupture (n=3). 
 
In the univariate analysis (Table 3), the tumor burden at listing did not differ between the groups. 
Female sex (p=0.03) and peak AFP ≥400ng/ml (p=0.0007), tumor burden at LT/dropout, and tumor 
progression on the waiting list (p=0.03) were associated with dropout. 
 
Multivariate analysis was performed using sex, duration on waiting list, peak AFP >400ng/ml, and 
tumor progression on waiting list as explanatory variables. Other significant variables in the 
univariate analysis were not included as they either measured concurrently with the outcome (tumor 
burden at LT/dropout), or were reflected in a statistically more powerful way using categorical 
variables (change in tumor burden). In the multivariate analysis, both tumor progression on waiting 
list (HR 4.973 [1.599 – 15.464], p=0.006) and peak AFP ≥400ng/ml (HR 4.604 [1.660 – 12.768], p=0.003) 
were independently associated with dropout. 
 
3. Post-LT HCC recurrence 
More than a third of the patients who had transplantation (n=24, 35%) developed recurrence after a 
median time of 17 months (IQR 8 – 25). The cumulative risk of recurrence was 13% at 1 year, 34% at 3 
years, and 41% at 5 years. In the univariate analysis, no tested variables were associated with 
recurrence (Supplementary Table 2). 
 
Lungs (n = 9) were the most common site of HCC recurrence followed by bone (n = 8), liver (n = 5), 
and lymph nodes (n = 5), whereas adrenal glands and abdominal wall were infrequent sites of 
recurrence. All patients with recurrence were considered for curative treatment (surgery or ablation). 
Seven (29%) patients underwent curative treatment (surgery, ablation), while 8 (33%) underwent 
non-curative treatment (radiotherapy, palliative surgery, Sorafenib treatment), and the rest (n=9, 
38%) received best supportive care. 
 
The median survival period from the time of LT (60 months [IQR 37 – 70] vs. 27 months [IQR 14 – 32], 
p=0.004) and the median survival from the time of recurrence (32 months [IQR 25 – 36] vs. 7 months 
[IQR 5 – 13], p=0.004) were significantly better for those who received curative treatment compared 
to others (figure 2).  
 
4. Survival from the time of listing and LT 
The median follow-up from the time of listing (all 96 patients) was 34 months (IQR 13 – 68). The 
actuarial patient survival rate was 76% at 1 year, 56% at 3 years, and 47% at 5 years from listing. 
 
The median follow-up from the time of LT (69 patients) was 39 months (IQR 24 – 80). The actuarial 
survival rate was 93% at 1 year, 71% at 3 years, and 66% at 5 years from LT. Survival from the time of 
LT was not associated with any of the tested variables (Supplementary Table 3). 
 
The number of living donor LT has remained relatively unchanged despite the gradual increase in the 
number of deceased donor LT for advanced HCC. Overall survival from the time of listing (48 vs. 50 
months; p= 0.86) and from the time of transplantation (39 vs. 45 months; p=0.93) did not differ 




This study evaluates the outcomes of patients listed for LT with advanced HCC who would have 
received palliative treatment at most Western centers. One fourth of the listed patients dropped out; 
peak AFP ≥400ng/ml and tumor progression on waiting list independently predicted dropout. The 5-
year post-LT survival was 66%. 
 
The patient survival of this series is lower than those within Milan criteria [12], but much better than 
the reported outcomes with palliative treatment, whether taken from the time of transplantation 
(71% at 3 years, 66% at 5 years) or from the time of listing (56% at 3 years, 47% at 5 years). For selected 
patients with non-transplantable HCC (i.e. beyond the Milan criteria), TACE barely accomplished a 3-
year survival rate of 30% even in experienced centers [9, 10]. The use of TACE with External Beam 
Radiotherapy [16] or Sorafenib [17, 18] also failed to demonstrate a satisfactory patient survival. 
Suboptimal survival (3-year survival of ~20%) has also been reported with Yttrium-90 selective 
internal radiation therapy in patients with intermediate-stage HCC deemed unsuitable for LT [19-21]. 
Thus, in the absence of comparable treatment options, it is not unreasonable to consider 
transplantation as a preferred alternative. On the other hand, it is necessary to be aware that the 
costs associated with LT are significantly higher than palliative therapies [22]. The estimated average 
total health care cost (2013 US$) of LT for HCC is approximately $211,286 (95%CI $193,919 – 
$228,654). The cost of palliative TACE is approximately $39,294 (95%CI $20,455 – $58,133) and 
systemic therapy (Sorafenib) is approximately $45,802 (95%CI $32,143 – $59,461) (personal 
communication – Hla-Hla Thein). However, despite the increased costs, the quality-adjusted life year 
is likely better with LT than with palliative treatments. 
 
As clinical practice moves towards personalized medicine, it becomes more crucial that all treatment 
options are presented to the patients and their families. Transplantation seems a better choice for 
selected patients with advanced HCC, but it is limited by the scarce resource of donated organs. 
Deciding when it is acceptable to allocate deceased donor grafts to patients with advanced HCC will 
depend on the regional waiting list and organ availability. Expansion of HCC transplant criteria can 
be justified only if it upholds fair organ allocation. Introduction of direct anti-viral agents against 
hepatitic C is expected to increase the availability of grafts [23]; thus expansion of HCC criteria may 
become feasible [24]. However, this opportunity may never materialize due to the impending 
steatohepatitis epidemic [25]. Another alternative would be living donor LT. This does not affect the 
candidacy of others, and the outcomes are comparable to deceased donor LT [26, 27]; therefore, 
would be a preferred option for selected patients with advanced HCC. The equivalence of HCC 
recurrence and patient survival between deceased donor and living donor LT of the present analysis 
further supports this notion. However, living donor LT must be undertaken in centers with extensive 
experience due to safety concerns of donors [28].  
 
The waiting list dropout was almost 30%. Higher dropout rates have also been reported previously in 
patients with HCC beyond the traditional criteria [29, 30]. Both AFP and tumor progression (tumor 
biological factors), but not tumor burden (size and numbers) were independently associated with 
dropout. The predictive role of tumor biology over tumor burden also has been shown in previous 
studies. In a recent study from the USCF group, AFP ≥500ng/ml and rapid tumor progression 
predicted dropout even in patients with very early stage HCC (single tumor <2cm) [31]. In another 
study, which included patients with HCC within and beyond Milan, the response to therapy was the 
only predictor of dropout, irrespective of tumor staging [32]. Likewise, a high AFP levels, but not total 
tumor volume was associated with waiting list dropout [33]. 
 
Post-transplant HCC recurrence was also found to be higher than in patients within traditional 
criteria. However, the 5-year post-LT survival was 66%. It is likely that the aggressive treatment of 
recurrence played a role in achieving such acceptable survival rates. The benefits of such aggressive 
treatment has also been demonstrated previously [34, 35]. The high recurrence rate may raise 
concerns over offering LT to this group of patients. However, it is important to recognize that patient 
survival, not recurrence, is the most clinically relevant and decisive outcome measure of 
transplantation [36]. 
 
Against expectations, the duration on waiting list did not impact post-LT survival. This contradicts 
the recent suggestion of implementing a period of observation to identify unfavorable tumor 
behavior before listing/transplantation [37-39]. One likely explanation for this discrepancy is the 
unaccounted period between the diagnosis of HCC (by the Hepatologist/Gastroenterologist/Family 
Physician) and listing, resulting in a bias towards the null. A substantial number of patients progress 
beyond the ETC during this period and are turned-down before they are formally assessed for LT.  
 
This study has strengths and limitations. The use of radiological parameters rather than explant 
parameters in the analysis made the findings reflect prospective decision-making in day-to-day 
practice. On the other hand, being a single center, retrospective study with relatively limited number 
of patients should be considered a limitation. Some comparisons may have been affected by the 
relatively small cohort. In addition, during the 15-year study period, there were significant 
advancements in bridging therapy and a shift toward a more aggressive management of HCC for 
patients on the waiting list, which had the potential for an impact on the results. Independent 
validation of this study results is therefore needed. 
 
Efforts to expand the traditional HCC allocation criteria is already underway [24, 40]. One such 
example would be the introduction of ‘Up-to-seven’ criteria by Mazzaferro (who initially proposed 
the Milan criteria) and colleagues [41]. Similarly, the emphasis on tumor biology (such as tumor 
differentiation, tumor response to bridging/downstaging therapies and AFP) rather than tumor 
burden in selecting patients for LT is gaining momentum [11, 24, 40, 42]. Therefore, it is not 
unreasonable to speculate that LT will emerge as an acceptable treatment choice for selected 
patients with advanced HCC in the near future. Certain transplant programs in Turkey and India seem 
to follow an unrestricted tumor burden policy, similar to that of the ETC [43]. It is crucial that these 
programs publish their long-term outcome results, which may further encourage other transplant 
programs to expend their allocation policy. In addition, the future of LT for advanced HCC relies on 
the availability of donor organs and living donor LT likely will play a crucial role in this. Where 
available, the option of living donor LT should be discussed and offered to all patients with advanced 
HCC. 
 
In conclusion, LT offers a 5-year survival rate of 66% for selected patients with advanced HCC and is 
a preferable alternative to palliation. Living donor LT may be the best option for this cohort as it will 
not negatively impact others on the waiting list.
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TABLES 
Table 1: Characteristics of all patients (n=96) listed for liver transplantation with advanced 
hepatocellular carcinoma, but within the Extended Toronto Criteria. 
 
AFP, alpha fetoprotein; ALD, alcohol-related liver disease; DDLT, deceased donor liver transplantation; HBV, chronic 
hepatitis B viral infection; HCC, hepatocellular carcinoma; HCV, chronic hepatitis C viral infection; LDLT, living donor liver 
transplantation; LT, liver transplantation; MELD, Model for End-stage Liver Disease score; NASH, non-alcohol-related 
steatohepatitis; PEI, percutaneous ethanol injection; RFA, radiofrequency ablation; SBRT, stereotactic body radiation 
therapy; TACE, transarterial chemoembolization; UCSF, University of California San Francisco. 
*Expressed as percentage of those who received bridging therapy (n=62). 
Expressed as percentage of those who underwent liver transplantation (n=69). 
 
 
Median or Number 
(IQR or %) 
Age at listing (years) 59 (52 – 63) 
Male sex 83 (86%) 
Etiology of liver disease HCV 41 (43%) 
 HBV 24 (25%) 
 ALD 18 (19%) 
 NASH 6 (6%) 
 Other 7 (7%) 
Duration on waiting list (months) 6 (3 – 9) 
Sodium-MELD at listing 12 (9 – 16) 
Peak AFP on waiting list (ng/ml) 87 (15 – 806) 
Peak AFP ≥400 ng/ml 29 (30%) 
Tumor burden at listing Total number of HCC lesions 5 (3 – 8) 
 Diameter of the largest target lesion (cm) 4.4 (2.6 – 6.3) 
 Total diameter of target lesions (cm) 8.9 (6.4 – 12.7) 
Tumor burden at LT or dropout Total number of HCC lesions 6 (2 – 11) 
 Diameter of the largest target lesion (cm) 3.0 (1.2 – 5.8) 
 Total diameter of target lesions (cm) 6.3 (1.2 – 11.4) 
Number of patients received bridging therapy 62 (65%) 
Modality of bridging therapy used TACE 47 (76%*) 
 RFA 18 (29%*) 
 PEI 4 (6%*) 
 SBRT 4 (6%*) 
Change in tumor burden Complete response 7 (7%) 
 Partial response 23 (24%) 
 Stable disease 11 (11%) 
 Progressive disease 55 (57%) 
Change in tumor burden 
(reclassified) 
Non-progressive disease 41 (43%) 
Progressive disease 55 (57%) 
Waiting list outcome Dropout 27 (28%) 
 Transplantation 69 (72%) 
Donor type DDLT 57 (83%) 
 LDLT 12 (17%) 
Table 2: Comparison between patients who received bridging therapy (n=62) and patients who did not receive bridging therapy (n=34).  
 
Abbreviations: AFP, alpha fetoprotein; ALD, alcohol-related liver disease; HBV, chronic hepatitis B viral infection; HCC, hepatocellular carcinoma; HCV, chronic hepatitis C viral infection; LT, 
liver transplantation; MELD, Model for End-stage Liver Disease score; NASH, non-alcohol-related steatohepatitis. A p-value <0.05 is indicated in bold.
 
Bridging therapy (n=62) No bridging therapy (n=34) 
p-value median or number 
(IQR or %) 
median or number 
(IQR or %) 
Age at listing (years) 58 (51 – 62) 61 (56 – 64) 0.06 
Male sex 54 (87%) 29 (85%) 0.80 
Etiology of liver disease HCV 24 (39%) 17 (50%) 
0.02 
 HBV 20 (32%) 4 (12%) 
 ALD 8 (13%) 10 (29%) 
 NASH 3 (5%) 3 (9%) 
 Other 7 (11%) 0 (0%) 
Duration on waiting list (months) 6 (3 – 9) 5 (3 – 8) 0.55 
Sodium-MELD at listing 11 (9 – 13) 16 (12 – 20) < 0.001 
Peak AFP ≥400 ng/ml 21 (34%) 8 (24%) 0.29 
Tumor burden at listing Total number of HCC lesions 4 (2 – 9) 6 (3 – 7) 0.41 
 Diameter of the largest target lesion (cm) 5.2 (2.6 – 7.3) 3.5 (2.6 – 5.2) 0.14 
 Total diameter of target lesions (cm) 9.0 (6.2 – 14.2) 8.0 (6.4 – 11.4) 0.57 
Tumor burden at LT or dropout Total number of HCC lesion 4 (2 – 11) 8 (6 – 11) 0.002 
 Diameter of the largest target lesion (cm) 1.8 (0.0 – 4.1) 4.6 (3.2 – 7.1) < 0.001 
 Total diameter of target lesions (cm) 2.1 (0.0 – 5.6) 11.4 (8.4 – 14.8) < 0.001 
Progressive disease on waiting list (according to mRECIST) 30 (48%) 25 (74%) 0.02 
Waiting list outcome Dropout 14 (23%) 13 (38%) 
0.10 
 LT 48 (77%) 21 (62%) 
Table 3: Comparison between patients who underwent liver transplantation (n=69) and who dropped out (n=27). 
 
Abbreviations: AFP, alpha fetoprotein; ALD, alcohol-related liver disease; HBV, chronic hepatitis B viral infection; HCC, hepatocellular carcinoma; HCV, chronic hepatitis C viral infection; LT, 




Dropouts (n=27) Transplanted (n=69) 
p-value 
Multivariate analysis 
median or number 
(IQR or %) 
median or number 
(IQR or %) 
hazard ratio (95% CI) p-value 
Age at listing (years) 60 (50 – 65) 59 (52 – 62) 0.57   
Male sex 20 (74%) 63 (91%) 0.03 - 0.39 
Etiology of liver disease HCV 13 (48%) 28 (40%) 
0.86 
  
 HBV 7 (26%) 17 (25%)  
 ALD 4 (15%) 14 (20%)  
 NASH 2 (7%) 4 (6%)  
 Other 1 (4%) 6 (9%)  
Duration on waiting list (months) 7 (4 – 11) 5 (3 – 8) 0.08 - 0.75 
Sodium-MELD at listing 13 (9 – 17) 11 (9 – 16) 0.57   
Peak AFP ≥400 ng/ml 15 (56%) 14 (20%) 0.0007 4.604 (1.660 – 12.768) 0.003 
Tumor burden at listing Total number of HCC lesions 7 (3 – 13) 5 (3 – 7) 0.27   
 Diameter of the largest target lesion (cm) 4.5 (2.9 – 5.9) 4.4 (2.6 – 6.4) 1.0   
 Total diameter of target lesions (cm) 8.9 (5.8 – 14.9) 8.9 (6.4 – 11.7) 0.83   
Tumor burden at LT or dropout Total number of HCC lesions 10 (6 – 29) 4 (2 – 9) 0.003   
 Diameter of the largest target lesion (cm) 4.9 (1.9 – 6.6) 2.6 (1.0 – 4.2) 0.047   
 Total diameter of target lesions (cm) 10.1 (3.7 – 13.7) 3.3 (1 – 9.9) 0.04   
Progressive disease on waiting list (according to mRECIST) 22 (81%) 33 (48%) 0.03 4.973 (1.599 – 15.464) 0.006 
Supplementary Table 1: Overall change in tumor burden according to the modified Response Evaluation Criteria in Solid Tumors (mRECIST) 
 
Overall tumor response Target lesion response  Non-target lesion response 
Complete response Complete response AND Complete response 
Partial response Complete response or partial response AND Incomplete response / stable disease 
Stable disease Stable disease AND Complete response or incomplete response / stable disease 
Progressive disease Progressive disease OR Progressive disease 
 
Up to five lesions were identified as target lesions instead of two as with mRECIST. 
Target lesion response: complete response: disappearance of any intratumoral arterial enhancement in all target lesions; partial response – at least a 30% reduction in the sum of diameter 
of viable target lesions; progressive disease – at least a 20% increment in the sum of diameter of viable target lesions; stable disease – a change in the sum of diameter of viable target lesions 
which cannot be categorized as partial response or progressive disease. 
Non-target lesion response: complete response – disappearance of intratumoral arterial enhancement in all non-target lesions; incomplete response / stable disease – persistence of 
intratumoral arterial enhancement in one or more non-target lesions; progressive disease – appearance of new lesion/s or unequivocal increase in size of existing non-target lesion/s. 
Supplementary Table 2: Post-transplantation HCC recurrence (n=69). 
 
 
Abbreviations: AFP, alpha fetoprotein; ALD, alcohol-related liver disease; HBV, chronic hepatitis B viral infection; HCC, 
hepatocellular carcinoma; HCV, chronic hepatitis C viral infection; LT, liver transplantation; MELD, Model for End-stage 





hazard ratio (95% CI) p-value 
Age at listing (years) 0.984 (0.936 – 1.033) 0.51 
Male sex 0.629 (0.187 – 2.110) 0.45 
Etiology of liver disease HCV 1.0 - 
 HBV 0.550 (0.196 – 1.547) 0.26 
 ALD 0.629 (0.205 – 1.931) 0.42 
 NASH - - 
 Other 0.581 (0.131 – 2.582) 0.48 
Duration on waiting list (months) 1.013 (0.939 – 1.092) 0.74 
Sodium-MELD at listing 0.923 (0.834 – 1.022) 0.13 
Peak AFP ≥400 ng/ml 1.344 (0.531 – 3.397) 0.53 
Tumor burden at listing Total number of HCC lesions 1.009 (0.969 – 1.050) 0.68 
 Diameter of the largest target lesion 1.056 (0.938 – 1.189) 0.37 
 Total diameter of target lesions 1.036 (0.967 – 1.110) 0.31 
Tumor burden at LT Total number of HCC lesions 1.008 (0.990 – 1.027) 0.37 
 Diameter of the largest target lesion 1.036 (0.904 – 1.188) 0.61 
 Total diameter of target lesions 1.015 (0.957 – 1.076) 0.63 
Progressive disease on waiting list (according to mRECIST) 1.217 (0.546 – 2.711) 0.63 
Donor type – living donor liver transplantation 1.286 (0.480 – 3.447) 0.62 
Supplementary Table 3: Patient survival from the time of transplantation (n=69). 
 
 
Abbreviations: AFP, alpha fetoprotein; ALD, alcohol-related liver disease; HBV, chronic hepatitis B viral infection; HCC, 
hepatocellular carcinoma; HCV, chronic hepatitis C viral infection; LT, liver transplantation; MELD, Model for End-stage 
Liver Disease score; NASH, non-alcohol-related steatohepatitis. 
 
 Univariate analysis 
 hazard ratio (95% CI) p-value 
Age at listing (years) 0.981 (0.936 – 1.028) 0.42 
Male sex 0.630 (0.185 – 2.142) 0.46 
Etiology of liver disease HCV 1.0 - 
 HBV 0.654 (0.227 – 1.882) 0.43 
 ALD 0.478 (0.135 – 1.696) 0.25 
 NASH 0.871 (0.112 – 6.757) 0.90 
 Other 0.626 (0.135 – 2.897) 0.55 
Duration on waiting list (months) 1.040 (0.972 – 1.112) 0.25 
Sodium-MELD at listing 0.951 (0.859 – 1.052) 0.33 
Peak AFP ≥400 ng/ml 1.132 (0.420 – 3.053) 0.81 
Tumor burden at listing Total number of HCC lesions 1.000 (0.952 – 1.051) 1.0 
 Diameter of the largest target lesion 1.002 (0.884 – 1.135) 0.97 
 Total diameter of target lesions 0.996 (0.921 – 1.076) 0.92 
Tumor burden at LT Total number of HCC lesions 0.998 (0.971 – 1.026) 0.89 
 Diameter of the largest target lesion 1.044 (0.918 – 1.188) 0.51 
 Total diameter of target lesions 1.009 (0.956 – 1.065) 0.75 
Progressive disease on waiting list (according to mRECIST) 1.469 (0.640 – 3.374) 0.37 




Flow chart representation of the study cohort (n=96).  
 
Figure 2 
Kaplan-Meier survival estimates of patients who developed hepatocellular carcinoma recurrence 
following transplantation from the time of liver transplantation and from the time of diagnosis of 
recurrence. The solid line represents patients who underwent curative treatment and the interrupted 
line represents patients who underwent non-curative treatment. 
